Evidence map›Paper›PMID 42650533›Full record

ArticleFoods (Basel, Switzerland)2026

Identification and Characterization of Novel DPP-IV Inhibitory Peptides from

Kota Ebato, Haruka Kobayashi, Hiroaki Tsutsumi, Yoko Iijima, Kenjiro Sugiyama

Abstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kota EbatoApplied Chemistry and Chemical Engineering Program, Graduate School of Engineering, Kogakuin University, Hachioji 192-0015, Tokyo, Japan.
Haruka KobayashiDepartment of Applied Chemistry, School of Advanced Engineering, Kogakuin University, Hachioji 192-0015, Tokyo, Japan.
Hiroaki TsutsumiHolistic Beauty Research Center, Wamiles Cosmetics Inc., Yokohama 233-0003, Kanagawa, Japan.
Yoko IijimaApplied Chemistry and Chemical Engineering Program, Graduate School of Engineering, Kogakuin University, Hachioji 192-0015, Tokyo, Japan.ORCID 0000-0001-9021-6136
Kenjiro SugiyamaDepartment of Applied Chemistry, School of Advanced Engineering, Kogakuin University, Hachioji 192-0015, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science JP26K05548The Tojuro Iijima Foundation for Food Science and Technology
6 · The paper itself

Abstract

As the prevalence of type 2 diabetes increases rapidly, the demand for natural origin dipeptidyl peptidase-IV (DPP-IV) inhibitors with fewer side effects is increasing. In this study, protein-rich

Indexed as

bioactive peptidedipeptidyl peptidase-IV (DPP-IV)Limnospiraprotein hydrolysatetype 2 diabetes

Identifiers

PMID42650533
PMCPMC13512118

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.